enGene Therapeutics, Inc. (ENGN)
1.81
+0.03
(+1.69%)
USD |
NASDAQ |
Aug 24, 16:00
1.82
+0.01
(+0.55%)
After-Hours: 20:00
enGene Therapeutics Enterprise Value : -105.95M for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | -105.95M |
| August 20, 2026 | -106.62M |
| August 19, 2026 | -101.26M |
| August 18, 2026 | -109.97M |
| August 17, 2026 | -111.31M |
| August 14, 2026 | -111.31M |
| August 13, 2026 | -111.98M |
| August 12, 2026 | -111.31M |
| August 11, 2026 | -103.27M |
| August 10, 2026 | -107.96M |
| August 07, 2026 | -104.61M |
| August 06, 2026 | -104.61M |
| August 05, 2026 | -104.61M |
| August 04, 2026 | -105.28M |
| August 03, 2026 | -106.62M |
| July 31, 2026 | -105.28M |
| July 30, 2026 | -107.29M |
| July 29, 2026 | -105.28M |
| July 28, 2026 | -107.29M |
| July 27, 2026 | -107.29M |
| July 24, 2026 | -103.27M |
| July 23, 2026 | -98.58M |
| July 22, 2026 | -101.26M |
| July 21, 2026 | -95.90M |
| July 20, 2026 | -99.92M |
| Date | Value |
|---|---|
| July 17, 2026 | -103.27M |
| July 16, 2026 | -96.57M |
| July 15, 2026 | -97.91M |
| July 14, 2026 | -98.24M |
| July 13, 2026 | -100.59M |
| July 10, 2026 | -97.91M |
| July 09, 2026 | -96.57M |
| July 08, 2026 | -100.59M |
| July 07, 2026 | -96.57M |
| July 06, 2026 | -97.24M |
| July 02, 2026 | -105.95M |
| July 01, 2026 | -107.29M |
| June 30, 2026 | -109.30M |
| June 29, 2026 | -105.95M |
| June 26, 2026 | -107.96M |
| June 25, 2026 | -106.62M |
| June 24, 2026 | -107.96M |
| June 23, 2026 | -110.64M |
| June 22, 2026 | -111.98M |
| June 18, 2026 | -109.97M |
| June 17, 2026 | -108.63M |
| June 16, 2026 | -107.96M |
| June 15, 2026 | -106.62M |
| June 12, 2026 | -116.67M |
| June 11, 2026 | -115.33M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Aurinia Pharmaceuticals, Inc. | 1.834B |
| Medicus Pharma Ltd. | 20.94M |
| Sirona Biochem Corp. | -- |
| Xenon Pharmaceuticals, Inc. | 4.955B |
| Psyence Biomedical Ltd. | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -30.23M |
| Total Expenses (Quarterly) | 30.23M |
| EPS Diluted (Quarterly) | -0.4335 |
| Earnings Yield | -120.5% |
| Normalized Earnings Yield | -120.25 |